AbbVie (NYSE:ABBV) Stock Price Down 2% – Time to Sell?

Shares of AbbVie Inc. (NYSE:ABBV) were down 2% during trading on Thursday . The company traded as low as $223.02 and last traded at $224.1250. Approximately 5,294,746 shares were traded during trading, a decline of 29% from the average daily volume of 7,508,581 shares. The stock had previously closed at $228.72.

Trending Headlines about AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Board declared a quarterly cash dividend of $1.73 per share, reinforcing AbbVie’s income profile (Dividend King status) and supporting long-term investor appeal. AbbVie Declares Quarterly Dividend
• Positive Sentiment: Coverage and retail-focussed pieces highlight AbbVie as a durable dividend stock to hold for multi-year income, which can underpin demand from yield-focused investors. 2 Dividend Stocks to Hold for the Next 5 Years
• Positive Sentiment: Pipeline progress is getting attention — recent filings (e.g., Rinvoq for vitiligo) and broader post-Humira portfolio developments prompt some investors to re-evaluate AbbVie’s growth outlook beyond legacy Humira sales. Should AbbVie’s (ABBV) Post-Humira Pipeline Progress Prompt a Fresh Look From Investors?
• Positive Sentiment: AbbVie reported completion of a VOLITE skin-quality trial milestone — clinical progress in dermatology could support commercial upside for portfolio assets if follow-up data read out positively. AbbVie’s VOLITE Skin Quality Trial Completion: What It Means for ABBV Investors
• Neutral Sentiment: Analyst and media pieces (Zacks, Yahoo, others) are re-assessing AbbVie after strong earnings and new filings; this keeps the stock in focus but doesn’t move consensus decisively — coverage is mixed between positive read-throughs and valuation scrutiny. Top Analyst Reports for AbbVie, RTX & IBM
• Negative Sentiment: Evercore lowered its price target slightly (from $232 to $228) and flagged that while Tremfya is gaining share, future earnings growth may be limited — that analyst caution helps explain downward pressure on the stock today. Evercore Notes AbbVie Inc.’s (ABBV) Tremfya Gains Market Share, But Future Earnings Growth May Be Limited

Wall Street Analyst Weigh In

Several research firms recently commented on ABBV. Scotiabank began coverage on shares of AbbVie in a research note on Thursday, November 13th. They set a “sector outperform” rating and a $280.00 target price for the company. Piper Sandler upped their price objective on shares of AbbVie from $289.00 to $299.00 and gave the company an “overweight” rating in a research report on Wednesday. Morgan Stanley increased their target price on shares of AbbVie from $269.00 to $270.00 and gave the company an “overweight” rating in a research note on Thursday, February 5th. Weiss Ratings restated a “hold (c)” rating on shares of AbbVie in a research note on Wednesday, January 21st. Finally, DZ Bank cut AbbVie from a “buy” rating to a “hold” rating and set a $237.00 price target for the company. in a report on Tuesday, November 4th. Two equities research analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating and nine have given a Hold rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $251.56.

AbbVie Stock Down 2.0%

The stock has a market cap of $396.12 billion, a price-to-earnings ratio of 94.97, a price-to-earnings-growth ratio of 0.81 and a beta of 0.35. The company’s 50-day moving average is $224.01 and its 200-day moving average is $221.68.

AbbVie (NYSE:ABBV) last released its quarterly earnings data on Wednesday, February 4th. The company reported $2.71 earnings per share for the quarter, beating the consensus estimate of $2.65 by $0.06. The company had revenue of $16.62 billion for the quarter, compared to analyst estimates of $16.39 billion. AbbVie had a negative return on equity of 4,184.47% and a net margin of 6.91%.The company’s revenue was up 10.0% compared to the same quarter last year. During the same period in the prior year, the company posted $2.16 EPS. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. On average, research analysts forecast that AbbVie Inc. will post 12.31 earnings per share for the current year.

Institutional Investors Weigh In On AbbVie

Several institutional investors and hedge funds have recently made changes to their positions in the company. Ellenbecker Investment Group boosted its position in AbbVie by 0.8% in the third quarter. Ellenbecker Investment Group now owns 5,334 shares of the company’s stock valued at $1,235,000 after buying an additional 44 shares in the last quarter. Bank of Jackson Hole Trust raised its stake in shares of AbbVie by 0.6% in the fourth quarter. Bank of Jackson Hole Trust now owns 7,213 shares of the company’s stock valued at $1,648,000 after acquiring an additional 44 shares during the last quarter. Security National Bank of Sioux City Iowa IA raised its stake in shares of AbbVie by 0.3% in the third quarter. Security National Bank of Sioux City Iowa IA now owns 15,382 shares of the company’s stock valued at $3,562,000 after acquiring an additional 45 shares during the last quarter. Matthew Goff Investment Advisor LLC boosted its holdings in shares of AbbVie by 0.3% in the 3rd quarter. Matthew Goff Investment Advisor LLC now owns 17,561 shares of the company’s stock worth $4,066,000 after acquiring an additional 45 shares in the last quarter. Finally, Centennial Wealth Advisory LLC grew its position in AbbVie by 2.2% during the 3rd quarter. Centennial Wealth Advisory LLC now owns 2,089 shares of the company’s stock worth $484,000 after acquiring an additional 45 shares during the last quarter. Institutional investors and hedge funds own 70.23% of the company’s stock.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.